$2.76
0.72% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US55279B2025
Symbol
MEIP
Sector
Industry

MEI Pharma, Inc. Stock price

$2.76
+0.03 1.10% 1M
-0.34 10.97% 6M
-3.04 52.41% YTD
-3.85 58.25% 1Y
-40.27 93.59% 3Y
-25.98 90.40% 5Y
-104.28 97.42% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.02 0.72%
ISIN
US55279B2025
Symbol
MEIP
Sector
Industry

Key metrics

Market capitalization $18.39m
Enterprise Value $-8.52m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.20
P/B ratio (TTM) P/B ratio 0.74
Dividend yield 0.00%
Last dividend (FY24) $1.75
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-38.19m
Free Cash Flow (TTM) Free Cash Flow $-43.65m
Cash position $26.91m
EPS (TTM) EPS $-6.99
P/E forward negative
Short interest 1.48%
Show more

Is MEI Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

MEI Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a MEI Pharma, Inc. forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a MEI Pharma, Inc. forecast:

Buy
33%
Hold
67%

Financial data from MEI Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.66 0.66
64% 64%
-
-0.66 -0.66
101% 101%
-
- Selling and Administrative Expenses 21 21
28% 28%
-
- Research and Development Expense 16 16
55% 55%
-
-38 -38
197% 197%
-
- Depreciation and Amortization 0.66 0.66
64% 64%
-
EBIT (Operating Income) EBIT -38 -38
204% 204%
-
Net Profit -47 -47
213% 213%
-

In millions USD.

Don't miss a Thing! We will send you all news about MEI Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MEI Pharma, Inc. Stock News

Neutral
Business Wire
14 days ago
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and...
Neutral
Business Wire
2 months ago
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenhe...
Neutral
Business Wire
4 months ago
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company's strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of its assets for its stockholders. The Company intends to ev...
More MEI Pharma, Inc. News

Company Profile

MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Head office United States
CEO Justin File
Employees 28
Founded 2000
Website www.meipharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today